Fig. 5From: Switching to brolucizumab: injection intervals and visual, anatomical and safety outcomes at 12 and 18 months in real-world eyes with neovascular age-related macular degenerationEffect of baseline VA on CMT at Month 12. CI, confidence interval; CMT, central macular thickness; Q, quarter; VA, visual acuityBack to article page